Angiochem crosses BBB, shows safety, efficacy

Posted on October 19, 2009
Filed Under MRSA | Leave a Comment

Angiochem announced today that its lead drug candidate, ANG1005, has demonstrated a favourable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas.

Source:Angiochem crosses BBB, shows safety, efficacy

Comments

Leave a Reply